Not only that but the EV of Race (i.e. minus cash on hand) is rapidly approaching USD100 million. Further depreciation in the share price and/or AUD will knock it into double digits. Surely there's a point where it becomes attractive for someone to try and pick up the lot. Clinical effectiveness in AML alone should justify the current price, and they could get cardio-protection, FTO, RC220 (plus the other formulation alluded to), and everything else thrown in as a gamble.
Ann: Race Strategic Update August 2023, page-156
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |